Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: OSBPL7

Gene summary for OSBPL7

Gene summary.

Gene information	Species	Human
	Gene symbol	OSBPL7
	Gene ID	114881
	Gene name	oxysterol binding protein like 7
	Gene Alias	ORP7
	Cytomap	17q21.32
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	Q8WXP9

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
114881	OSBPL7	HTA11_2487_2000001011	Human	Colorectum	SER	5.58e-04	2.70e-01	-0.1808
114881	OSBPL7	HTA11_347_2000001011	Human	Colorectum	AD	5.36e-08	2.44e-01	-0.1954

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0042176	Colorectum	AD	regulation of protein catabolic process	160/3918	391/18723	1.06e-19	7.34e-17	160
GO:0009896	Colorectum	AD	positive regulation of catabolic process	180/3918	492/18723	4.33e-16	1.94e-13	180
GO:1903362	Colorectum	AD	regulation of cellular protein catabolic process	109/3918	255/18723	2.14e-15	6.08e-13	109
GO:0010498	Colorectum	AD	proteasomal protein catabolic process	174/3918	490/18723	3.18e-14	7.66e-12	174
GO:0031331	Colorectum	AD	positive regulation of cellular catabolic process	156/3918	427/18723	4.68e-14	1.05e-11	156
GO:1903050	Colorectum	AD	regulation of proteolysis involved in cellular protein catabolic process	92/3918	221/18723	2.04e-12	3.19e-10	92
GO:0045732	Colorectum	AD	positive regulation of protein catabolic process	92/3918	231/18723	3.85e-11	4.47e-09	92
GO:0045862	Colorectum	AD	positive regulation of proteolysis	129/3918	372/18723	4.04e-10	3.46e-08	129
GO:0061136	Colorectum	AD	regulation of proteasomal protein catabolic process	75/3918	187/18723	1.65e-09	1.20e-07	75
GO:0010506	Colorectum	AD	regulation of autophagy	111/3918	317/18723	3.57e-09	2.35e-07	111
GO:1903364	Colorectum	AD	positive regulation of cellular protein catabolic process	62/3918	155/18723	4.66e-08	2.51e-06	62
GO:1903052	Colorectum	AD	positive regulation of proteolysis involved in cellular protein catabolic process	53/3918	133/18723	4.93e-07	1.85e-05	53
GO:1901800	Colorectum	AD	positive regulation of proteasomal protein catabolic process	44/3918	114/18723	1.18e-05	2.62e-04	44
GO:0010876	Colorectum	AD	lipid localization	120/3918	448/18723	1.59e-03	1.33e-02	120
GO:0006869	Colorectum	AD	lipid transport	108/3918	398/18723	1.67e-03	1.39e-02	108
GO:0097305	Colorectum	AD	response to alcohol	71/3918	253/18723	4.01e-03	2.80e-02	71
GO:0008202	Colorectum	AD	steroid metabolic process	85/3918	319/18723	8.07e-03	4.75e-02	85
GO:00421761	Colorectum	SER	regulation of protein catabolic process	126/2897	391/18723	5.33e-17	2.52e-14	126
GO:19033621	Colorectum	SER	regulation of cellular protein catabolic process	91/2897	255/18723	1.22e-15	5.36e-13	91
GO:19030501	Colorectum	SER	regulation of proteolysis involved in cellular protein catabolic process	77/2897	221/18723	7.85e-13	2.00e-10	77

Page: 1 2

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

OSBPL7

SNV

Missense_Mutation

novel

c.1175G>T

p.Ser392Ile

p.S392I

Q9BZF2

protein_coding

deleterious(0)

probably_damaging(0.994)

TCGA-A7-A0CE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

OSBPL7

SNV

Missense_Mutation

novel

c.455N>T

p.Ser152Leu

p.S152L

Q9BZF2

protein_coding

tolerated(0.38)

benign(0)

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

OSBPL7

SNV

Missense_Mutation

c.2455N>A

p.Val819Met

p.V819M

Q9BZF2

protein_coding

deleterious(0)

probably_damaging(0.959)

TCGA-A8-A09M-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

paclitaxel

OSBPL7

SNV

Missense_Mutation

rs764860598

c.400G>A

p.Val134Met

p.V134M

Q9BZF2

protein_coding

deleterious(0)

possibly_damaging(0.671)

TCGA-BH-A0HY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

taxotere

OSBPL7

SNV

Missense_Mutation

rs181669798

c.1574N>A

p.Arg525His

p.R525H

Q9BZF2

protein_coding

tolerated(0.89)

benign(0.001)

TCGA-XX-A89A-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

OSBPL7

insertion

Frame_Shift_Ins

novel

c.1176_1177insTTCCTATG

p.Ile393PhefsTer3

p.I393Ffs*3

Q9BZF2

protein_coding

TCGA-A7-A0CE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

OSBPL7

deletion

Frame_Shift_Del

novel

c.320delN

p.Lys107ArgfsTer36

p.K107Rfs*36

Q9BZF2

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

OSBPL7

SNV

Missense_Mutation

rs763820323

c.1450N>T

p.Arg484Cys

p.R484C

Q9BZF2

protein_coding

deleterious(0)

possibly_damaging(0.765)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

OSBPL7

SNV

Missense_Mutation

rs138224859

c.542N>A

p.Arg181Gln

p.R181Q

Q9BZF2

protein_coding

tolerated(1)

benign(0.003)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

OSBPL7

SNV

Missense_Mutation

novel

c.2026N>A

p.Ala676Thr

p.A676T

Q9BZF2

protein_coding

deleterious(0.05)

possibly_damaging(0.869)

TCGA-EK-A2RM-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1